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ABSTRACT
Background: Understanding the possible role of  visfatin in the 
pathogenesis of  beta‑thalassemia major (BTM) and its relationship 
with markers of  endothelial function could help us to provide 
more effective therapeutic approaches for treatment of  patients 
with BTM and its related complications. The aim of  current study 
was to compare serum level of  visfatin between patients with BTM 
and control group and determine its correlation with markers of  
endothelial function, intracellular adhesion molecule (ICAM) and 
vascular adhesion molecule (VCAM).
Methods: In this case‑control study, patients with BTM receiving 
regular blood transfusion aged 10‑20 years and a group of  healthy 
subjects were enrolled. Selected subjects examined clinically 
and venous blood samples obtained for visfatin, ICAM, VCAM, 
cholesterol, triglyceride, high density lipoprotein cholesterol, 
low density lipoprotein cholesterol and ferritin measurements. 
Mean (standard deviation) of  studied laboratory measurements 
compared in two studied groups and the relation between visfatin 
and ICAM, VCAM, ferrittin, body mass index determined.
Results: In this study 31 patients with BTM and 30 healthy controls 
studied. Mean of  visfatin was significantly higher in patients with 
BTM than control group (133.9 ± 60.1 vs. 43.3 ± 27.9, P < 0.001).
Conclusions: The higher level of  visfatin among patients with BTM 
indicated the possible inflammatory role of  this adipocytokine in 
BTM. It seems that for understanding the underlying mechanisms 
and its relation with vascular inflammatory markers and endothelial 
function further studies with larger sample size is needed.
Keywords: Beta‑thalassemia major, endothelial function, 
intracellular adhesion molecule, vascular adhesion molecule, 
vascular inflammatory markers, visfatin
INTRODUCTION
Beta‑thalassemia major (BTM) considered as one of  the most 
prevalent hemoglobinopathies in Mediterranean region including 
Iran.[1] BTM characterized by failure of  the haemoglobin 
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synthesis leading to excess beta‑globin chains, 
haemolysis and impair erythropoiesis.[2]
Though higher standards of  care in BTM 
patients including blood transfusions combined 
with adequate chelation therapy have led to 
enhance years of  survival but stimulantly 
the rate of  its related complications such as 
cardiovascular disease (CVD) and arterial and 
venous thromboembolic events have increased 
also.[3,4]
The underlying mechanisms of  BTM related 
complications were not determined clearly. 
Evidences indicated that inflammation and 
endothelial dysfunction have an important role 
in the pathophysiology of  BTM and its related 
complications.[5‑7]
Endothelium has a crucial role in the 
modulation of  vascular tone. Furthermore 
endothelial dysfunction could be representative 
of  vascular inflammation.[8] It is suggested that 
endothelial dysfunction through factors such as 
endothelial adhesion of  thalassemic erythrocytes 
in microvessels, chronic hypercoagulable state and 
increased erythrocyte aggregation have role in this 
regard.[9‑11]
It is believed that a chronic inflammatory 
state with increased level of  pro‑inflammatory 
cytokines is present in patients with BTM.[5] 
The most frequently studied adipocytokines are 
leptin and adiponectin.[12,13] Visfatin is a 
novel pro‑inflammatory adipocytokine which 
predominantly expressed in visceral adipose 
tissue.[14] Several experimental studies indicated 
its role in inflammatory processes and chronic 
inflammatory diseases.[15,16] The potential 
properties of  visfatin makes it as a target for novel 
therapeutic strategies in different inflammatory 
and metabolic diseases.[17] The role of  visfatin in 
BTM has not studied yet.
It seems that understanding its possible role in 
the pathogenesis of  BTM and its relationship with 
markers of  endothelial function could help us to 
provide more effective therapeutic approaches for 
treatment of  patients with BTM and its related 
complications. The aim of  current study was to 
compare serum level of  visfatin between patients 
with BTM and control group and determine its 
correlation with markers of  endothelial function, 
intracellular adhesion molecule (ICAM) and 
vascular adhesion molecule (VCAM).
METHODS
In this case‑control study patients with 
BTM receiving regular blood transfusion aged 
10‑20 years and a group of  age, sex, body mass 
index and pubertal stages matched healthy subjects 
were enrolled.
Patients with BTM were selected from the Imam 
Ali clinic of  endocrinology and hematology, affiliated 
to Shahrekord University of  Medical Sciences 
from. Diagnosis of  BTM was based on clinical and 
hematological (complete blood count and hemoglobin 
electrophoresis) evaluation. Control groups selected 
from healthy subjects referred to Imam Ali pediatrics 
clinic for regular annual follow‑up.
Subjects who were smoker or had a history of  
diabetes mellitus, hypertension, hypothyroidism, 
hyperlipidemia, valvular heart disease, heart failure 
and renal or hepatic disease were excluded from the 
study.
The protocol of  study was approved by 
Pediatrics Review Board and Regional Bioethics 
Committee of  Shahrekord University of  Medical 
Sciences. Written informed consent was obtained 
from all selected patients or their parents.
Selected patients were recalled and demographic 
characteristics and details related to the history of  
disease in thalassemic patients were recorded by a 
trained nurse using a questionnaire.
Selected subjects examined clinically by a 
pediatrician (anthropometrics measurements, vital 
signs and presence of  any complications) and 
venous blood samples obtained for visfatin, ICAM, 
VCAM, cholesterol, triglyceride, high density 
lipoprotein cholesterol (HDL‑C), low density 
lipoprotein cholesterol (LDL‑C) and ferritin 
measurements. Blood samples obtained after 12 h 
fasting at 7:30‑9:30 am. In thalassemic patients 
blood samples obtained before blood transfusion.
Mean (standard deviation [SD]) of  studied 
laboratory measurements compared in two studied 
groups.
Laboratory measurements
Visfatin level was measured by ELISA method 
using Human Visfatin Kit (ADIPOGEN Inc., 
South Korea) with the sensitivity of  30 pg/ml.
ICAM and VCAM measured by ELISA 
method using Bender Med system, Human 
sVCAM‑1‑BM232‑Austria and Bender Med 
System, Human sICAM‑1‑BM 201‑Austria.
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Normal range of  visfatin, ICAM and VCAM was 
14‑50 ng/ml, 347‑629 ng/ml and 675‑1693 ng/ml, 
respectively.
Ferritin level was measured by ELISA 
method using human from Human company 
kit (Germany).
Cholesterol, triglyceride, HDL‑C and LDL‑C 
were measured using Pars Azmoon Kits (Tehran, 
Iran).
Statistical analysis
Obtained data analyzed using SPSS 
version 18 (SPSS Inc., Chicago, IL, U.S.A.) 
software. Quantitive variables were presented as 
mean (SD). Mean of  the study variables between 
groups were compared using t‑test. Frequencies 
of  higher level of  visfatin, ICAM and VCAM 
between groups were compared using Chi‑square 
test. P < 0.05 were considered significant.
RESULTS
In this study 31 patients with BTM and 30 healthy 
controls studied. Demographic and laboratory 
findings of  studied population are presented in 
Table 1. High level of  visfatin was reported in 
25 (80.64%) and 9 (30.00%) of  patients in BTM 
and control groups, respectively (P < 0.001). There 
was not any cases with higher rate of  ICAM and 
VCAM.
DISCUSSION
In this study we investigated the serum 
concentration of  visfatin as well as ICAM and 
VCAM, the vascular inflammatory markers 
in patients with BTM and a group of  healthy 
subjects to determine their possible role in the 
pathophysiology of  BTM. Our findings indicated 
that visfatin was significantly higher in patients 
with BTM but there was not any relationship 
between visfatin and ICAM, VCAM and ferritin in 
two studied groups.
As mentioned the quality of  care and life 
expectancy of  patients with BTM have improved 
significantly due to proper treatment strategies 
but in the other hand the rate of  BTM related 
CVD, endocrine and metabolic complication have 
increased also.[18] Though the responsible factors 
have not determined clearly but inflammation and 
endothelial dysfunction considered as potential 
factors in this field.[5,19]
The role of  some adipocytokines and 
inflammatory factors in the pathogenesis of  BTM 
and its complication have been studied in previous 
studies.[20] In this study we investigated the role of  
visfatin in this field. To the best of  our knowledge 
it is the first study which evaluated the role of  
visfatin in BTM.
The role of  visfatin in the pathogenesis 
of  other diseases such as diabetes mellitus, 
insulin resistance, atopic dermatitis, chronic 
kidney disease and rheumatic disease have been 
reported.[21‑24]
Kim et al. in Korea have indicated that visfatin 
could increases expression of  ICAM and VCAM 
through reactive oxygen species‑dependent NF‑κB 
activation in endothelial cells.[25]
Evidences demonstrated that ICAM and 
VCAM considered as early endothelial dysfunction 
markers.[26] Thus in this study we examined 
the relation between visfatin with mentioned 
endothelial factors. It is supposed that in the 
presence of  relationship between visfatin and 
vascular inflammatory factors we could identify 
high risk population by measuring the marker 
and consequently we could provide preventative 
strategies.
Table 1: Mean±SD of demographic and laboratory variables 
in patients with beta-thalassemia major and healthy controls
Variables Patients with 
beta‑thalassemia 
major n=31
Control 
group 
n=30
P value
Female/male 12/19 11/19 0.54
Age (years) 14.45±4.82 14.56±4.29 0.92
BMI (kg/m2) 18.37±2.72 19.55±2.72 0.07
Ferritin (ng/ml) 926.43±216.40 139.6±80.13 <0.001
ICAM (ng/ml) 15.25±6.44 17.72±8.12 0.215
VCAM (ng/ml) 57.64±15.89 81.98±14.72 0.025
Visfatin (ng/ml) 133.99±60.10 43.35±27.93 <0.001
Cholesterol 
(mg/dl)
116.58±21.12 116.26±20.44 0.95
Triglyceride 
(mg/dl)
120.09±36.73 81.53±22.59 0.06
LDL‑C (mg/dl) 58.96±18.02 61.43±19.16 0.6
HDL‑C (mg/dl) 36.41±7.4 38.4±4.37 0.21
SD=Standard deviation, BMI=Body mass index, 
ICAM=Intracellular adhesion molecule, VCAM=Vascular 
adhesion molecule, LDL‑C=Low density lipoprotein 
cholesterol, HDL‑C=High‑density lipoprotein cholesterol
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In this study though serum visfatin was higher 
in patients than control group but there was not 
significant relationship between visfatin and ICAM 
and VCAM. The level of  ICAM was not different 
significantly in control and patients with BTM. 
Regarding VCAM, though it was significantly 
higher in control group than patients with BTM 
but it was in normal range of  VCAM (normal 
range = 675‑1693 ng/ml).
There was not any similar study in this field. But 
there were some similar studies which examined 
the role of  other adipocytokines in this field.
Aggeli et al. in Greece evaluated serum levels of  
inflammatory mediators including interleukin‑6, 
sVCAM‑1 and sICAM‑1 in 67 patients with BTM 
and 71 healthy controls. They showed that patients 
with BTM had impaired endothelial function and 
increased level of  studied markers. They concluded 
that inflammation and endothelial dysfunction 
may have potential role in occurrence of  BTM 
related complications.[19]
In another recent study in Greece, Chaliasos 
et al. have examined the serum levels of  leptin and 
adiponectin and their correlation with vascular 
inflammation markers including endothelin (ET)‑1, 
ET‑3, VCAM‑1, ICAM‑1, L‑selectin and E‑selectin 
in 28 patients with BTM and a group of  healthy 
controls. Their results indicated that patients with 
BTM have significantly lower level of  leptin and 
higher level of  adiponectin than control group. 
Patients had higher level of  ET‑1, VCAM‑1 and 
E‑selectin than control group.[27]
They did not find any correlations between 
leptin and vascular inflammation markers. There 
was positive correlation between adiponectin 
and ET‑1. They concluded that from studied 
adipocytokines, adiponectin have a possible role 
in endothelial damage and CVD complication in 
patients with BTM.
In current study similarly we did not find any 
significant correlation between visfatin and ICAM 
and VCAM. Obtained data could be explained 
as follows considering the low mean age of  our 
studied patients, possibly the process of  endothelial 
dysfunction has not initiated yet. Also, it may be 
due to that it was the first stage of  endothelial 
dysfunction when even we have not seen any 
increasing in vascular inflammation markers levels.
A confirmatory data was that lipids level both 
in patients and control groups were similar. Mean 
age of  our studied population was 14.5 years 
whereas in the study of  Aggeli et al. and Chaliasos 
et al. mean age of  studied population was 24.6 and 
18 years respectively.
In addition mean of  ferritin was also lower 
than the mentioned studies. It may be due to 
lower duration of  the disease. Lower duration 
of  the disease could also explain the lack of  
relationship between mentioned factors with 
ferritin. Another explanation was small sample 
size of  patients.
The limitation of  current study was that 
endothelial function was not evaluated by 
intima‑media thickness or flow‑mediated 
dilatation. However they considered as reliable 
and noninvasive method for this purpose.
CONCLUSIONS
The higher level of  visfatin among patients with 
BTM indicated the possible inflammatory role 
of  this adipocytokine in BTM. It seems that for 
understanding the underlying mechanisms and its 
relation with vascular inflammatory markers and 
endothelial function further studies with larger 
sample size is needed.
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